Trial
NCT03655444
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Eli Lilly and Company
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Abemaciclib
Why stopped
Provider of drug decided to discontinue study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-03